| Code | CSB-RA356436MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to dusigitumab, targeting insulin-like growth factor 1 (IGF1), a critical peptide hormone that mediates growth hormone effects and regulates cellular proliferation, differentiation, and survival. IGF1 functions primarily through binding to the IGF1 receptor, activating downstream signaling pathways including PI3K/AKT and MAPK cascades that control metabolism and cell growth. Dysregulation of IGF1 signaling is implicated in various pathological conditions, including cancer progression, metabolic disorders, and growth abnormalities, making it a significant target for therapeutic and investigational research.
Dusigitumab is an investigational monoclonal antibody designed to neutralize IGF1, thereby blocking IGF1R activation and inhibiting tumor growth in IGF1-dependent malignancies. This biosimilar antibody provides researchers with a valuable tool for investigating IGF1-mediated signaling mechanisms, exploring therapeutic blockade strategies, and studying the role of IGF1 in oncology, endocrinology, and developmental biology research. It enables comprehensive analysis of IGF1 pathway modulation in various experimental models and disease contexts.
There are currently no reviews for this product.